RGC Stock Overview
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company.
Regencell Bioscience Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$32.14|
|52 Week High||US$59.00|
|52 Week Low||US$6.00|
|1 Month Change||-15.42%|
|3 Month Change||32.70%|
|1 Year Change||257.11%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||206.10%|
Recent News & Updates
|RGC||US Pharmaceuticals||US Market|
Return vs Industry: RGC exceeded the US Pharmaceuticals industry which returned 2% over the past year.
Return vs Market: RGC exceeded the US Market which returned -13% over the past year.
|RGC Average Weekly Movement||13.0%|
|Pharmaceuticals Industry Average Movement||11.7%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.2%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: RGC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: RGC's weekly volatility has decreased from 44% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Regencell Bioscience Holdings Fundamentals Summary
|RGC fundamental statistics|
Is RGC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RGC income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.35|
|Net Profit Margin||0.00%|
How did RGC perform over the long term?See historical performance and comparison
Is RGC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RGC?
Other financial metrics that can be useful for relative valuation.
|What is RGC's n/a Ratio?|
Price to Book Ratio vs Peers
How does RGC's PB Ratio compare to its peers?
|RGC PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
TARS Tarsus Pharmaceuticals
VRNA Verona Pharma
JUSH.F Jushi Holdings
OCUL Ocular Therapeutix
RGC Regencell Bioscience Holdings
Price-To-Book vs Peers: RGC is expensive based on its Price-To-Book Ratio (21.2x) compared to the peer average (3.9x).
Price to Earnings Ratio vs Industry
How does RGC's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Book vs Industry: RGC is expensive based on its Price-To-Book Ratio (21.2x) compared to the US Pharmaceuticals industry average (2x)
Price to Book Ratio vs Fair Ratio
What is RGC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||21.2x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate RGC's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of RGC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RGC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RGC's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Regencell Bioscience Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Regencell Bioscience Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of RGC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
How has Regencell Bioscience Holdings performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: RGC is currently unprofitable.
Growing Profit Margin: RGC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if RGC's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare RGC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RGC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).
Return on Equity
High ROE: RGC has a negative Return on Equity (-23.72%), as it is currently unprofitable.
Discover strong past performing companies
How is Regencell Bioscience Holdings's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: RGC's short term assets ($19.0M) exceed its short term liabilities ($1.4M).
Long Term Liabilities: RGC has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: RGC's net debt to equity ratio (6.6%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if RGC's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if RGC has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RGC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Regencell Bioscience Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RGC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RGC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RGC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RGC's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RGC has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Yat-Gai Au (49 yo)
Mr. Yat-Gai Au serves as the Chief Financial Officer of Armitage Technologies Holding Ltd. Mr. Au served as Compliance Officer and Executive Director of Armitage Technologies Holding Ltd. He joined Armitag...
Experienced Management: RGC's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.
Experienced Board: RGC's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: RGC insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.
Regencell Bioscience Holdings Limited's employee growth, exchange listings and data sources
- Name: Regencell Bioscience Holdings Limited
- Ticker: RGC
- Exchange: NasdaqCM
- Founded: 2014
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$418.234m
- Shares outstanding: 13.01m
- Website: https://www.regencellbioscience.com
Number of Employees
- Regencell Bioscience Holdings Limited
- First Commercial Building
- 11th Floor
- Causeway Bay
- Hong Kong
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/09 00:00|
|End of Day Share Price||2022/08/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.